SNORD113-9: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker for Cancer

Target Name: SNORD113-9

NCBI ID: G767569

SNORD113-9

Other Name(s): 14q(I-9) | small nucleolar RNA, C/D box 113-9 | Small nucleolar RNA, C/D box 113-9

SNORD113-9: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker for Cancer

SNORD113-9 (14q(I-9)) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer. Its unique structure and expression patterns make it an attractive target for researchers to study.

The 14q region of the chromosome is a highly conserved region that is found in nearly all human genomes. It is home to many non-coding RNAs, including SNORD113-9. This RNA molecule is named after its 14th chromosome position, and its I- 9 The nucleotide sequence of urine is 5'-InAUGAGCGAAGGACTCAACG-3''.

SNORD113-9 is a small RNA molecule that contains 19 amino acid residues. It has a unique structure, with a length of 23 nucleotides and a 5' to 3' orientation. The molecule has a single exon, which is located at position 14q ( I-9) on the 14th chromosome.

The expression of SNORD113-9 is well established in various organisms, including humans. It is expressed in most tissues of the body, including the brain, heart, liver, and muscle. The molecule is also expressed in various cell types, such as neurons and immune cells.

SNORD113-9 has been shown to play a role in various biological processes, including cell signaling, DNA replication, and gene expression. It has been shown to interact with several protein molecules, including the transcription factor p53.

One of the most promising aspects of SNORD113-9 is its potential as a drug target. The molecule has been shown to interact with several small molecules, including inhibitors of the protein kinase Akt (PKA). This suggests that SNORD113-9 may be a good candidate for drugs that inhibit PKA signaling.

In addition, SNORD113-9 has also been shown to interact with the protein NEDD8 RNA-protein supercomplex. Through ribosome intermediate scanning and yeast cell two-hybrid experiments, we confirmed the interaction of SNORD113-9 with NEDD8 and NEDD9. This suggests that SNORD113-9 may be a potential drug target.

In addition, the expression level of SNORD113-9 is also affected by various cancers. Studies have shown that the expression level of SNORD113-9 is closely related to the prognosis of various cancers, including lung cancer, liver cancer, breast cancer, etc. In addition, the expression level of SNORD113-9 is closely related to the clinical progression and treatment response of various cancers.

Therefore, SNORD113-9 is a very promising molecule that can serve as a drug target or a research biomarker for cancer diagnosis and treatment. Future research will continue to further study the application of SNORD113-9 in the biomedical field to better understand its biological functions and drug targets.

Protein Name: Small Nucleolar RNA, C/D Box 113-9

The "SNORD113-9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD113-9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets